Sandbox brain abscess: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
==brain abscess==
==Brain Abscess <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from Sanford Guide to Antimicrobial Therapy (2010); and
 
J Neurosci Rural Pract. 2013 August; 4(Suppl 1): S67–S81<ref name="pmid3808066">Carpenter D, Jackson T, Hanley MR (1987) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=3808066 Protein kinase Cs. Coping with a growing family.] ''Nature'' 325 (7000):107-8. [http://dx.doi.org/10.1038/325107a0 DOI:10.1038/325107a0] PMID: [http://pubmed.gov/3808066 3808066]</ref></SMALL></SMALL></SMALL></SMALL></SMALL>
 
<font color="#FF4C4C">'''Click on the following categories to expand treatment regimens.'''</font>
 
{|
{|
| valign=top |
| valign=top |
Line 10: Line 15:
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table01" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Primary source'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Primary Source'''
</font>
</font>
</div>
</div>
Line 16: Line 21:
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table02" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Contiguous source'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Contiguous Source'''
</font>
</font>
</div>
</div>
Line 22: Line 27:
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table03" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Post-traumatic'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Post-Traumatic'''
</font>
</font>
</div>
</div>
Line 28: Line 33:
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table04" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Post-surgical'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Post-Surgical'''
</font>
</font>
</div>
</div>
Line 34: Line 39:
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table05" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''metastatic or cryptogenic'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Metastatic or Cryptogenic'''
</font>
</font>
</div>
</div>
Line 40: Line 45:
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<div class="mw-customtoggle-table06" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 225px; background: #4479BA;">
<font color="#FFF">
<font color="#FFF">
&nbsp;&nbsp;▸&nbsp;&nbsp;'''metastatic or cryptogenic'''
&nbsp;&nbsp;▸&nbsp;&nbsp;'''Haematogenous Abscess'''
</font>
</font>
</div>
</div>
Line 155: Line 160:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Haematogenous Abscess }}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center |{{fontcolor|#FFF|Haematogenous Abscess}}<sup>¶</sup>
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen<sup></sup>'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen<sup>#</sup>'''''


|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP]]: 3.75-7.5 mg/kg IV/ po q6-12h  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim]]: 3.75-7.5 mg/kg IV/ po q6-12h  


|-
|-
Line 167: Line 172:
|-
|-


| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[SMX]]: 18.75-37.5 mg/kg/day IV/po q6-12h
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfamethoxazole]]: 18.75-37.5 mg/kg/day IV/po q6-12h
|-
|-


Line 177: Line 182:


|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP]]: 3.75-7.5 mg/kg IV/ po q6-12h  
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim]]: 3.75-7.5 mg/kg IV/ po q6-12h  
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[SMX]]: 18.75-37.5 mg/kg/day IV/po q6-12h
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Sulfamethoxazole]]: 18.75-37.5 mg/kg/day IV/po q6-12h
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
Line 229: Line 234:
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[TMP-SMX]] 5/25 mg/kg po or IV q12h for 30 days '''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Trimethoprim-Sulfamethoxazole ]] 5/25 mg/kg po or IV q12h for 30 days '''''
|-
|-
|}
|}
|}
|}
|}
|}
<small><small><small><small><sup>†</sup>:If Pseudomonas aeruginosa is suspected.</small></small></small><small>
<small><small><small><small><sup>‡</sup>:The aim is  to keep the  serum levels at 15-25mg/L</small></small></small><small>
<small><small><small><small><sup>¶</sup>:After 3-6 wks of IV therapy, switch to po therapy. Immunocompetent pts: TMP-SMX, minocycline or AM-CL x 3+months. Immunocompromised pts: Treat with 2 drugs for at least one year.</small></small></small><small>
<small><small><small><small><sup>#</sup>: If multiorgan involvement some add amikacin 7.5 mg/kg q12h.

Revision as of 20:34, 27 January 2014

==Brain Abscess Adapted from Sanford Guide to Antimicrobial Therapy (2010); and

J Neurosci Rural Pract. 2013 August; 4(Suppl 1): S67–S81[1]

Click on the following categories to expand treatment regimens.

Brain Abscess

  ▸  Primary Source

  ▸  Contiguous Source

  ▸  Post-Traumatic

  ▸  Post-Surgical

  ▸  Metastatic or Cryptogenic

  ▸  Haematogenous Abscess

  ▸  Immunocompromised

Primary Source
Preferred Regimen
Cefotaxime 2 gm IV q4h
OR
Ceftriaxone 2 gm IV q12h
PLUS
Metronidazole 7.5 mg/kg q6h OR 5 mg/kg IV q12h
Alternative Regimen
Penicllin G 3-4 million units IV q4h
PLUS
Metronidazole 7.5 mg/kg q6h OR 15 mg/kg IV q12h
Contiguous source
Preferred Regimen
Metronidazole 500 mg/kg q8h
PLUS
Cefotaxime 2 g IV q6h
OR
Piperacillin/Tazobactam 4.5 g IV q6h
Post-traumatic
Preferred Regimen
Cefotaxime 2 g IV q6h
PLUS
Metronidazole 500 mg/kg q8h
PLUS OR NOT
Rifampin 10 mg/kg q24h
Post-surgical
Preferred Regimen
Linezolid 600 mg IV q12h
OR
Vancomycin 15 mg/kg loading dose or 10-15 mg/kg q6h followed by 40-60 mg/kg/24 hourly continuously infusion
PLUS
Rifampin 10 mg/kg qd
PLUS
Meropenem 1.5 g q6h or 2 g q8h
OR
Piperacillin/Tazobactam 4.5 g q6h
metastatic or cryptogenic
Preferred Regimen
Cefataxime 2 g IV q6h
PLUS OR NOT
Metronidazole 500 mg q8h
OR
Ampicillin/Sulbactam 100/50 mg/kg q6h
Haematogenous Abscess
Preferred Regimen#
Trimethoprim: 3.75-7.5 mg/kg IV/ po q6-12h
PLUS
Sulfamethoxazole: 18.75-37.5 mg/kg/day IV/po q6-12h
PLUS
Ceftriaxone 2 gm IV q12h
Alternative Regimen
Trimethoprim: 3.75-7.5 mg/kg IV/ po q6-12h
PLUS
Sulfamethoxazole: 18.75-37.5 mg/kg/day IV/po q6-12h
PLUS
Amikacin 7.5 mg/kg q12h
PLUS
Imipenem-Cilastatin 500 mg IV q6h
Immunocompromised
Preferred Regimen(for minimum of 6 wks after resolution of signs)
Pyrimethamine 200 mg po qd then 75 mg/day po
PLUS
Sulfadiazine: 1 gm po q6h if <60 kg, 1.5 gm po q6h if •60 kg
PLUS
Folinic acid 10–25 mg po qd
Alternative Regimen(for 4–6 wks after resolution of signs)
Pyrimethamine 200 mg po qd then 75 mg/day po
PLUS
Folinic acid 10–25 mg po qd
PLUS
Clindamycin 600 mg po IV q6h
OR
TMP/SMX 5/25 mg/kg po qd or IV bid
OR
Atovaquone 750 mg po q6h
Suppression therapy
Sulfadiazine: 2-4 g po q6-12h
PLUS
Pyrimethamine 25-50 mg po qd
PLUS
Folinic acid 10–25 mg po qd
OR
Trimethoprim-Sulfamethoxazole 5/25 mg/kg po or IV q12h for 30 days

:If Pseudomonas aeruginosa is suspected.

:The aim is to keep the serum levels at 15-25mg/L

:After 3-6 wks of IV therapy, switch to po therapy. Immunocompetent pts: TMP-SMX, minocycline or AM-CL x 3+months. Immunocompromised pts: Treat with 2 drugs for at least one year.

#: If multiorgan involvement some add amikacin 7.5 mg/kg q12h.

  1. Carpenter D, Jackson T, Hanley MR (1987) Protein kinase Cs. Coping with a growing family. Nature 325 (7000):107-8. DOI:10.1038/325107a0 PMID: 3808066